Vicore Pharma Ab (publ) logo

Vicore Pharma Ab (publ)(NASDAQ) VCRE

Market Cap$253.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-45%
5 YearN/A
1 YearN/A
1 Month-26%
$9.22
+4.54%
+0.40Today
After hours$9.00-$0.22 (-2.39%)
Vicore Pharma Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 9.002026-10-09
Vicore Pharma Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.54%USD 9.332026-10-02
1 month-25.5%USD 12.082026-09-09
3 month-34.69%USD 13.782026-07-10
Since inception-44.62%USD 16.252026-07-06

Vicore Pharma Ab (publ) Financials at a Glance

Market Cap

$253.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 1.33M

Net Income (TTM)

-SEK 272.50M

EPS (TTM)

-$2.04

P/E Ratio

-4.41

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$9.22

Volume

30,984

Open

$9.01

Previous Close

$9.00

Daily Range

$8.85 - $9.30

52-Week Range

$7.88 - $17.80

Estimated Earnings Date

Nov 5, 2026

VCRE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vicore Pharma Ab (publ)

Vicore Pharma Holding AB is a pharmaceutical company focused on developing innovative treatments for interstitial lung diseases and related conditions. Founded in 2000 and headquartered in Stockholm, Sweden, the company is dedicated to advancing its drug development programs, which include VP01, VP02, VP03, and VP04.

Products and Services
  • Development of drugs targeting interstitial lung diseases
  • Research programs aimed at related medical indications
  • Innovative therapeutic solutions in the biotechnology sector
Growth Outlook
  • Strong pipeline with multiple drug candidates in development
  • Increasing demand for treatments in the lung disease sector
  • Potential for strategic partnerships to enhance market reach
Financial Highlights
  • Recent quarterly revenue of 228,246 SEK, showing growth potential
  • Cash and short-term investments totaling 93,407,050 SEK
  • Current ratio of 12.68 indicates strong liquidity position
Vicore Pharma Holding AB is positioned in a niche market with significant growth potential, particularly in the treatment of interstitial lung diseases. The company's focus on innovative drug development is supported by a robust pipeline, which may attract interest from investors looking for opportunities in the biotechnology sector. Recent financial data indicates a solid liquidity position, with substantial cash reserves that can support ongoing research and development efforts. The increasing demand for effective treatments in this area further enhances the company's growth outlook, making it a noteworthy consideration for potential investors.
AI Generated • Oct 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

46

CEO

Ahmed S. Mousa

Website

www.vicorepharma.com

Headquarters

Stockholm, AB 111 27, SE

VCRE Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-21455.42%

Net Income Margin

-20489.51%

Return on Equity

-48.25%

Return on Capital

-41.48%

Return on Assets

-284.14%

Earnings Yield

-22.68%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$253.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

28.16M

Volume

30.98K

Avg. Volume

16.55K

Financials (TTM)

Gross Profit

SEK 1.33M

Operating Income

-SEK 285.35M

EBITDA

-SEK 248.71M

Operating Cash Flow

-SEK 225.86M

Capital Expenditure

SEK 0.00

Free Cash Flow

-SEK 225.86M

Cash & ST Invst.

SEK 93.41M

Total Debt

SEK 0.00

Vicore Pharma Ab (publ) Performance Analysis

Vicore Pharma Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 0N/A
20232023-12-31SEK 0N/A
20242024-12-31SEK 10,342,266N/A
20252025-12-31SEK 389,192-96.2%
Vicore Pharma Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-95.4%
Q42025-12-31419.0%
Q12026-03-3143.7%
Q22026-06-30-62.1%
Vicore Pharma Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK -3.84-20.4%
20232023-12-31SEK -2.95-23.1%
20242024-12-31SEK -1.17-60.5%
20252025-12-31SEK -2.0374.1%
Vicore Pharma Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3099.0%
Q42025-12-31-10405.8%
Q12026-03-3127.8%
Q22026-06-3098.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 228.25K

-86.9%

Gross Profit

SEK 228.25K

-86.9%

Gross Margin

100.00%

N/A

Market Cap

$253.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.85M

N/A

Employees

37

N/A

Net Income

-SEK 14.73M

+87.2%

EBITDA

SEK 0.00

+100.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 93.41M

N/A

Total Debt

SEK 0.00

N/A

Accounts Receivable

SEK 0.00

N/A

Inventory

SEK 0.00

N/A

Long Term Debt

SEK 0.00

N/A

Short Term Debt

SEK 0.00

N/A

Return on Assets

-2.84%

N/A

Return on Invested Capital

-3.23%

N/A

Free Cash Flow

-SEK 16.08M

+84.9%

Operating Cash Flow

-SEK 16.08M

+84.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVLNAvalyn Pharma Inc. Common Stock
$25.76+0.16%
LQDALiquidia Corporation
$27.38-2.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About VCRE

What is the current price of Vicore Pharma Ab (publ)?

Vicore Pharma Ab (publ) is trading at $9.00 per share.

What is the 52-week range for Vicore Pharma Ab (publ)?

Over the past 52 weeks, Vicore Pharma Ab (publ) has traded between $7.88 and $17.80.

How much debt does Vicore Pharma Ab (publ) have?

As of the most recent reporting period, Vicore Pharma Ab (publ) reported total debt of SEK 0.00.

How much cash does Vicore Pharma Ab (publ) have on hand?

Vicore Pharma Ab (publ) reported SEK 44.28M in cash and cash equivalents in its most recent financial results.

What is Vicore Pharma Ab (publ)’s dividend yield?

Vicore Pharma Ab (publ) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services